← Leaderboards
Takuma Uo
University Of Washington
$448,874
Attributed
$448,874
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $242.6K · FY2021–22$250K$187.5K$125K$62.5K$0
'21
'22
Funding mix
By agency
NIH$448,874 · 1
By mechanism
R21$448,874 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Wesley C Van Voorhis$32,631,211
- Stephen R Plymate$6,213,858
- Ke Hu$4,985,340
- Jennifer D Wu$10,794,755
- Frederick Simmons Buckner$14,937,505
Others in their field
Other Emerging Leaders on “Antiandrogen Therapy”
- Aaron Matthew Lebeau · University Of Wisconsin-Madison$4,885,889
- Boyang Wu · Washington State University$3,392,553
- Felix Yi-Chung Feng · University Of California, San Francisco$2,768,322
- Xiuping Yu · Louisiana State Univ Hsc Shreveport$1,714,354
- Franklin W Huang · Veterans Affairs Med Ctr San Francisco$999,080
- Ping Mu · Sloan-Kettering Inst Can Research$865,328
Research focus
Antiandrogen TherapyAntineoplastic AgentsAntiparasitic AgentsCancer EtiologyCastration Resistant Prostate CancerCell Cycle ArrestCell ProliferationCessation Of LifeClinicCryptosporidium ParvumDependenceDesignDrug CandidateDrug KineticsEnzymesExhibitsExome SequencingExperimental StudyFoundationsGenesGenetic ManipulationGlycolysisImproved OutcomeAndrogen Receptor
Grant awards (2)
Identifying primary targets of bumped kinase inhibitor derived compounds to improve utility as therapy for castration resistant prostate cancer$242,590
R21 · FY2022 · CA · contact PI
Identifying primary targets of bumped kinase inhibitor derived compounds to improve utility as therapy for castration resistant prostate cancer$206,284
R21 · FY2021 · CA · contact PI